Cited by 100Adipokines, Inflammation, and Metabolic DiseasesDiabetes, Cardiovascular Risks, and LipoproteinsAdipose Tissue and Metabolism

Zinc-α2-Glycoprotein Is Associated With Insulin Resistance in Humans and Is Regulated by Hyperglycemia, Hyperinsulinemia, or Liraglutide Administration

Open access
Yang, Mengliu, Liu, Rui, Li, Shu, Luo, Yu, Zhang, Yali, Zhang, Lili, Liu, Dongfang, Wang, Yaxu +5 more·2013·Diabetes Care

Abstract

OBJECTIVE: Zinc-α2-glycoprotein (ZAG) has been proposed to play a role in the pathogenesis of insulin resistance. Previous studies in humans and in rodents have produced conflicting results regarding the link between ZAG and insulin resistance. The objective of this study was to examine the relationships between ZAG and insulin resistance in cross-sectional and interventional studies. RESEARCH DESIGN AND METHODS: Serum ZAG (determined with ELISA) was compared with various parameters related to insulin resistance in subjects with normal glucose tolerance, impaired glucose tolerance (IGT), and newly diagnosed type 2 diabetes mellitus (T2DM), and in women with or without polycystic ovary syndrome (PCOS). Euglycemic-hyperinsulinemic clamps were performed in healthy and PCOS women. Real-time RT-PCR and Western blotting were used to assess mRNA and protein expression of ZAG. The effect of a glucagon-like peptide-1 agonist on ZAG was studied in a 12-week liraglutide treatment trial. RESULTS: Circulating ZAG was lower in patients with IGT and newly diagnosed T2DM than in controls. Circulating ZAG correlated positively with HDL cholesterol and adiponectin, and correlated inversely with BMI, waist-to-hip ratio, body fat percentage, triglycerides, fasting blood glucose, fasting insulin, HbA1c, and homeostasis model assessment of insulin resistance (HOMA-IR). On multivariate analysis, ZAG was independently associated with BMI, HOMA-IR, and adiponectin. ZAG mRNA and protein were decreased in adipose tissue of T2DM patients. Moreover, circulating ZAG levels were lower in women with PCOS than in women with high insulin sensitivity. Liraglutide treatment for 12 weeks significantly increased circulating ZAG levels. CONCLUSIONS: We conclude that ZAG may be an adipokine associated with insulin resistance.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc12-0940

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Yang, M., Liu, R., Li, S., Luo, Y., Zhang, Y., Zhang, L., Liu, D., Wang, Y., Xiong, Z., Boden, G., Chen, S., Li, L., & Yang, G.
Affiliations
  • Second Affiliated Hospital of Chongqing Medical University (CN)
  • Chongqing Medical University (CN)
  • Temple University (US)
Corresponding author
  • Chen, Shirong
  • Li, Ling
  • Yang, Gangyi
Venue
Diabetes Care
Published
2013-04-13
Volume
36
Issue
5
Pages
1074-1082
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2109300793
Cited by
100
References
27
Citations by year
2026: 4 · 2025: 6 · 2024: 13 · 2023: 8 · 2022: 5 · 2021: 7 · 2020: 10 · 2019: 9 · 2018: 7 · 2017: 7 · 2016: 8 · 2015: 8 · 2014: 7 · 2013: 1
FWCI
3.83
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Physiology › Adipose Tissue and Metabolism
Keywords
zinc-alpha2-glycoprotein, insulin resistance, type 2 diabetes, impaired glucose tolerance, polycystic ovary syndrome, adipokines, liraglutide, GLP-1 receptor agonists, adipose tissue, adiponectin, hyperinsulinemia, hyperglycemia, body mass index
MeSH terms
Liraglutide, Zn-Alpha-2-Glycoprotein, Adult, Aged, Cross-Sectional Studies, Diabetes Mellitus, Type 2, Female, Humans, Hyperglycemia, Hyperinsulinism, Insulin Resistance, Male, Middle Aged, Polycystic Ovary Syndrome, Seminal Plasma Proteins, Glucagon-Like Peptide 1, Adipokines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review